GenKyoTex S.A. 's GKT137831 Found To Reverse Fibrosis And Improve Survival In A Model Of Persistent Lung Fibrosis
4/10/2014 9:22:56 AM
GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. Collaborators led by Professor Victor Thannickal at the University of Alabama at Birmingham published the results in the April 9, 2014 issue of Science Translational Medicine. Genkyotex is investigating GKT137831 in a Phase II trial in patients with diabetic nephropathy, another progressive fibrotic disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by